For many children, asthma can be a constant specter, with attacks at the most inconvenient and terrifying times. New research ...

Children with mild asthma at low risk for severe exacerbations may not need daily or as-needed ICS, as GINA guidelines recommend.

In the first randomized controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children ...

A joint scientific study conducted by researchers at the Medical Research Institute of New Zealand, in collaboration with ...

A groundbreaking international study has shown that a 2-in-1 budesonide-formoterol inhaler is far more effective than the ...

New guidelines that seek to change how asthma is treated in Australia have been unveiled by Health Minister Mark Butler and ...

The 2018 Lancet Commission,1 After asthma: redefining airways diseases, made clear recommendations to improve outcomes for ...

Find out about this new study that suggest that the lung scarring that severe asthma can cause could be reversible.

Australia has overhauled the way asthma is treated, with doctors advised to stop prescribing blue “reliever” puffers alone amid evidence they leave patients at greater risk of severe attacks.

The National Asthma Council’s advice for treating the condition has been updated, advising doctors against solely prescribing blue puffers to patients.

The first head-to-head randomized clinical trial to compare biologics in severe chronic rhinosinusitis with nasal polyps ...